SpreeHealth
Drug price

Tiotropium: here's the fair price

This is what US pharmacies pay, on average, for tiotropium. Use it to spot a fair cash price, and feel good about asking for one.

Lowest generic tablet or capsule

Tiotropium 18 Mcg Cap-Inhaler

$356.89
pharmacy cost for 30

A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.

Your best move

Ask for generic Tiotropium 18 Mcg Cap-Inhaler. Pharmacies pay about $356.89 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.

Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.

Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.

Pharmacies near you

Your ZIP and location stay in your browser. We never store them.

Every strength and form

ProductPharmacy cost30 countEffective
TIOTROPIUM 18 MCG CAP-INHALERGeneric$11.90
per tablet or capsule
$356.8910/21/2026

Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.

Label basics

What it is used for (FDA label)

1 INDICATIONS AND USAGE STIOLTO RESPIMAT is a combination of tiotropium bromide, an anticholinergic and olodaterol, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) Important limitations: STIOLTO RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.1 ) STIOLTO RESPIMAT is NOT indicated to treat asthma. ( 1.1 ) 1.1 Maintenance Treatment of COPD STIOLTO RESPIMAT is a combination of tiotropium bromide and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including...

Common side effects (FDA label)

6 ADVERSE REACTIONS LABA, such as olodaterol, one of the active components in STIOLTO RESPIMAT, as monotherapy (without an inhaled corticosteroid) for asthma, increase the risk of asthma-related events. STIOLTO RESPIMAT is not indicated for the treatment of asthma [see Warning and Precautions (5.1) ]. The following adverse reactions are described, or described in greater detail, in other sections: Immediate hypersensitivity reactions [see Warnings and Precautions (5.4) ] Paradoxical bronchospasm [see Warnings and Precautions (5.5) ] Worsening of narrow-angle glaucoma [see Warnings and...

Drug interactions (from the label)

7 DRUG INTERACTIONS Other adrenergic drugs may potentiate effect. Use with caution. ( 5.3 , 7.1 ) Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. Use with caution. ( 7.2 , 7.3 ) MAO inhibitors, tricyclic antidepressants, and drugs that prolong QTc interval may potentiate effect on cardiovascular system. Use with extreme caution. ( 7.4 ) Beta-blockers may decrease effectiveness. Use with caution and only when medically necessary. ( 7.5 ) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of STIOLTO RESPIMAT with other anticholinergic-containing drugs. (...

Warnings (from the label)

5 WARNINGS AND PRECAUTIONS LABA as monotherapy (without an inhaled corticosteroid) for asthma increases the risk of serious asthma-related events. ( 5.1 ) Do not initiate STIOLTO RESPIMAT in acutely deteriorating COPD patients. ( 5.2 ) Do not use for relief of acute symptoms. Concomitant short-acting beta 2 -agonists can be used as needed for acute relief. ( 5.2 ) Do not exceed the recommended dosage. Excessive use of STIOLTO RESPIMAT, or use in conjunction with other medications containing LABA can result in clinically significant cardiovascular effects and may be fatal. ( 5.3 ) Immediate hypersensitivity reactions: Discontinue STIOLTO RESPIMAT at once and consider alternatives if...

Source: FDA drug label via openFDA, label effective 2025-06-30. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.